Hereditary breast cancer: The Era of new susceptibility genes

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Apostolou, Paraskevi ^a   Fostira, Florentia ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; BRIP1 PROTEIN; CHECKPOINT KINASE 2; FANCONI ANEMIA PROTEIN; MRE11 PROTEIN; NIBRIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53; RAD50 PROTEIN; RAD51C PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; XRCC2 PROTEIN; PROTEIN SERINE THREONINE KINASE; PTEN PROTEIN, HUMAN; STK11 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

BREAST CANCER; CANCER SUSCEPTIBILITY; COWDEN SYNDROME; EXON; FAMILIAL CANCER; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; MAMMOGRAPHY; MISSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARY CANCER; PENETRANCE; PEUTZ JEGHERS SYNDROME; REVIEW; RNA SPLICING; TUMOR SUPPRESSOR GENE; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84876591647     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/747318     Document Type: Review

References (130)

1. Ferlay J., Parkin D. M., Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 2010 46 4 765 781 2-s2.0-76049128595 10.1016/j.ejca.2009.12.014
2. Lalloo F., Evans D. G., Familial breast cancer. Clinical Genetics 2012 82 2 105 114
3. Yang X. R., Chang-Claude J., Goode E. L., Couch F. J., Nevanlinna H., Milne R. L., Gaudet M., Schmidt M. K., Broeks A., Cox A., Fasching P. A., Hein R., Spurdle A. B., Blows F., Driver K., Flesch-Janys D., Heinz J., Sinn P., Vrieling A., Heikkinen T., Aittomäki K., Heikkilä P., Blomqvist C., Lissowska J., Peplonska B., Chanock S., Figueroa J., Brinton L., Hall P., Czene K., Humphreys K., Darabi H., Liu J., Van 'T Veer L. J., Van Leeuwen F. E., Andrulis I. L., Glendon G., Knight J. A., Mulligan A. M., O'Malley F. P., Weerasooriya N., John E. M., Beckmann M. W., Hartmann A., Weihbrecht S. B., Wachter D. L., Jud S. M., Loehberg C. R., Baglietto L., English D. R., Giles G. G., McLean C. A., Severi G., Lambrechts D., Vandorpe T., Weltens C., Paridaens R., Smeets A., Neven P., Wildiers H., Wang X., Olson J. E., Cafourek V., Fredericksen Z., Kosel M., Vachon C., Cramp H. E., Connley D., Cross S. S., Balasubramanian S. P., Reed M. W. R., Dörk T., Bremer M., Meyer A., Karstens J. H., Ay A., Park-Simon T. W., Hillemanns P., Arias Pérez J. I., Rodríguez P. M., Zamora P., Benítez J., Ko Y. D., Fischer H. P., Hamann U., Pesch B., Brüning T., Justenhoven C., Brauch H., Eccles D. M., Tapper W. J., Gerty S. M., Sawyer E. J., Tomlinson I. P., Jones A., Kerin M., Miller N., McInerney N., Anton-Culver H., Ziogas A., Shen C. Y., Hsiung C. N., Wu P. E., Yang S. L., Yu J. C., Chen S. T., Hsu G. C., Haiman C. A., Henderson B. E., Le Marchand L., Kolonel L. N., Lindblom A., Margolin S., Jakubowska A., Lubiński J., Huzarski T., Byrski T., Górski B., Gronwald J., Hooning M. J., Hollestelle A., Van Den Ouweland A. M. W., Jager A., Kriege M., Tilanus-Linthorst M. M. A., Collée M., Wang-Gohrke S., Pylkäs K., Jukkola-Vuorinen A., Mononen K., Grip M., Hirvikoski P., Winqvist R., Mannermaa A., Kosma V. M., Kauppinen J., Kataja V., Auvinen P., Soini Y., Sironen R., Bojesen S. E., Dynnes Ørsted D., Kaur-Knudsen D., Flyger H., Nordestgaard B. G., Holland H., Chenevix-Trench G., Manoukian S., Barile M., Radice P., Hankinson S. E., Hunter D. J., Tamimi R., Sangrajrang S., Brennan P., McKay J., Odefrey F., Gaborieau V., Devilee P., Huijts P. E. A., Tollenaar R., Seynaeve C., Dite G. S., Apicella C., Hopper J. L., Hammet F., Tsimiklis H., Smith L. D., Southey M. C., Humphreys M. K., Easton D., Pharoah P., Sherman M. E., Garcia-Closas M., Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. Journal of the National Cancer Institute 2011 103 3 250 263 2-s2.0-79551694006 10.1093/jnci/djq526
4. Claus E. B., Risch N., Thompson W. D., Genetic analysis of breast cancer in the cancer and steroid hormone study. The American Journal of Human Genetics 1991 48 2 232 242 2-s2.0-0026092912 (Pubitemid 21891587)
5. Newman B., Austin M. A., Lee M., King M. C., Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proceedings of the National Academy of Sciences of the United States of America 1988 85 9 3044 3048 2-s2.0-2742525287
6. Hall J. M., Lee M. K., Newman B., Morrow J. E., Anderson L. A., Huey B., King M. C., Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990 250 4988 1684 1689 2-s2.0-0025613812 (Pubitemid 120031871)
7. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennet L. M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994 266 5182 66 71 2-s2.0-0028113345 (Pubitemid 24345325)
8. Walsh T., Lee M. K., Casadei S., Thornton A. M., Stray S. M., Pennil C., Nord A. S., Mandell J. B., Swisher E. M., King M. C., Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America 2010 107 28 12629 12633 2-s2.0-77955439715 10.1073/pnas.1007983107
9. Waters C. M., Hoover A. C., McClain L. C., Moore T. T., Rogers C. T., Thornton K., Current guidelines and best practice evidence for intensified/enhanced breast cancer screening in women with BRCA mutations. Journal for Nurse Practitioners 2009 5 6 447 453 2-s2.0-66549089038 10.1016/j.nurpra.2009.02.018
10. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S. J., Qin J., BASC, a super complex of BRCA1 -associated proteins involved in the recognition and repair of aberrant DNA structures. Genes and Development 2000 14 8 927 939 2-s2.0-0034655991 (Pubitemid 30253002)
11. Welcsh P. L., King M. C., BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human Molecular Genetics 2001 10 7 705 713 2-s2.0-0035057806 (Pubitemid 32331579)
12. Antoniou A., Pharoah P. D., Narod S., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. The American Journal of Human Genetics 2003 72 5 1117 1130 2-s2.0-0042888567 (Pubitemid 36530000)
13. Armaou S., Konstantopoulou I., Anagnostopoulos T., Razis E., Boukovinas I., Xenidis N., Fountzilas G., Yannoukakos D., Novel genomic rearrangements in the BRCA1 gene detected in greek breast/ovarian cancer patients. European Journal of Cancer 2007 43 2 443 453 2-s2.0-33846317838 10.1016/j.ejca.2006.09. 021 (Pubitemid 46123993)
14. Konstantopoulou I., Rampias T., Ladopoulou A., Koutsodontis G., Armaou S., Anagnostopoulos T., Nikolopoulos G., Kamakari S., Nounesis G., Stylianakis A., Karanikiotis C., Razis E., Gogas H., Keramopoulos A., Gaki V., Markopoulos C., Skarlos D., Pandis N., Bei T., Arzimanoglou I., Fountzilas G., Yannoukakos D., Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment 2008 107 3 431 441 2-s2.0-38649139360 10.1007/s10549-007-9571-2 (Pubitemid 351172120)
15. Johannesdottir G., Gudmundsson J., Bergthorsson J. T., Arason A., Agnarsson B. A., Eiriksdottir G., Johannsson O. T., Borg A., Ingvarsson S., Easton D. F., Egilsson V., Barkardottir R. B., High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Research 1996 56 16 3663 3665 2-s2.0-9444248601 (Pubitemid 26272009)
16. Roa B. B., Boyd A. A., Volcik K., Richards C. S., Ashkenazi jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics 1996 14 2 185 187 2-s2.0-0029794992 10.1038/ng1096-185 (Pubitemid 26338801)
17. Fostira F., Tsitlaidou M., Papadimitriou C., Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment 2012 134 1 353 362
18. Bryant H. E., Schultz N., Thomas H. D., Parker K. M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N. J., Helleday T., Specific killing of BRCA2 -deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005 434 7035 913 917 2-s2.0-17244375049 10.1038/nature03443 (Pubitemid 40559005)
19. Farmer H., McCabe H., Lord C. J., Tutt A. H. J., Johnson D. A., Richardson T. B., Santarosa M., Dillon K. J., Hickson I., Knights C., Martin N. M. B., Jackson S. P., Smith G. C. M., Ashworth A., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 434 7035 917 921 2-s2.0-17244373777 10.1038/nature03445 (Pubitemid 40559006)
20. Chen S., Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Journal of Clinical Oncology 2006 24 6 863 871 (Pubitemid 46638837)
21. Easton D., Cancer risks in BRCA2 mutation carriers: the breast cancer linkage consortium. Journal of the National Cancer Institute 1999 91 15 1310 1316 2-s2.0-0033523268 (Pubitemid 29387573)
22. Thorlacius S., Struewing J. P., Hartge P., Olafsdottir G. H., Sigvaldason H., Tryggvadottir L., Wacholder S., Tulinius H., Eyfjörd J. E., Population-based study of risk of breast cancer in carriers of BRCA2 mutation. The Lancet 1998 352 9137 1337 1339 2-s2.0-18344410703 10.1016/S0140-6736(98) 03300-5 (Pubitemid 28510913)
23. Lakhani S. R., Jacquemier J., Sloane J. P., Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. Journal of the National Cancer Institute 1998 90 15 1138 1145 2-s2.0-0033528059 (Pubitemid 28380718)
24. Foulkes W. D., BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Familial Cancer 2006 5 2 135 142 2-s2.0-33744760541 10.1007/s10689-005-2832-5 (Pubitemid 43824469)
25. Narod S. A., Foulkes W. D., BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer 2004 4 9 665 676 2-s2.0-4544374528 10.1038/nrc1431 (Pubitemid 39215065)
26. Saslow D., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: a Cancer Journal for Clinicians 2007 57 2 75 89 (Pubitemid 46535708)
27. Rebbeck T. R., Friebel T., Lynch H. T., Neuhausen S. L., Van't Veer L., Garber J. E., Evans G. R., Narod S. A., Isaacs C., Matloff E., Daly M. B., Olopade O. I., Weber B. L., Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. Journal of Clinical Oncology 2004 22 6 1055 1062 2-s2.0-1842614292 10.1200/JCO.2004.04. 188 (Pubitemid 41095038)
28. Kauff N. D., Satagopan J. M., Robson M. E., Scheuer L., Hensley M., Hudis C. A., Ellis N. A., Boyd J., Borgen P. I., Barakat R. R., Norton L., Castiel M., Nafa K., Offit K., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England Journal of Medicine 2002 346 21 1609 1615 2-s2.0-0037162115 10.1056/NEJMoa020119 (Pubitemid 34755668)
29. King M. C., Wieand S., Hale K., Lee M., Walsh T., Owens K., Tait J., Ford L., Dunn B. K., Costantino J., Wickerham L., Wolmark N., Fisher B., Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 national surgical adjuvant breast and bowel project (nsabp-p1) breast cancer prevention trial. Journal of the American Medical Association 2001 286 18 2251 2256 2-s2.0-0035861037 (Pubitemid 33063147)
30. Graveley B. R., Sorting out the complexity of SR protein functions. RNA 2000 6 9 1197 1211 2-s2.0-0033835333 10.1017/S1355838200000960
31. Cartegni L., Chew S. L., Krainer A. R., Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nature Reviews Genetics 2002 3 4 285 298 2-s2.0-0036207384 10.1038/nrg775 (Pubitemid 34279797)
32. Blencowe B. J., Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends in Biochemical Sciences 2000 25 3 106 110 2-s2.0-0034161419 10.1016/S0968-0004(00)01549-8 (Pubitemid 30122418)
33. Cartegni L., Wang J., Zhu Z., Zhang M. Q., Krainer A. R., ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Research 2003 31 13 3568 3571 2-s2.0-0042242582 10.1093/nar/gkg616 (Pubitemid 37442199)
34. Whiley P. J., Pettigrew C. A., Brewster B. L., Walker L. C., Spurdle A. B., Brown M. A., Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts. BMC Medical Genetics 2010 11 1, article 80 2-s2.0-77952725403 10.1186/1471-2350-11-80
35. Menéndez M., Castellsagué J., Mirete M., Pros E., Feliubadaló L., Osorio A., Calaf M., Tornero E., del Valle J., Fernández-Rodríguez J., Quiles F., Salinas M., Velasco A., Teulé A., Brunet J., Blanco I., Capellá G., Lázaro C., Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment 2012 132 3 979 992 2-s2.0-79959837874 10.1007/s10549-011-1661-5
36. Fackenthal J. D., Olopade O. I., Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nature Reviews Cancer 2007 7 12 937 948 2-s2.0-36448996703 10.1038/nrc2054 (Pubitemid 350165853)
37. Fackenthal J. D., Cartegni L., Krainer A. R., Olopade O. I., BRCA2 T2722R is a deleterious allele that causes exon skipping. The American Journal of Human Genetics 2002 71 3 625 631 2-s2.0-0036724459 10.1086/342192 (Pubitemid 34970133)
38. Moseley C. T., Mullis P. E., Prince M. A., Phillips J. A., An exon splice enhancer mutation causes autosomal dominant GH deficiency. Journal of Clinical Endocrinology and Metabolism 2002 87 2 847 852 2-s2.0-0036171787 10.1210/jc.87.2.847 (Pubitemid 34158262)
39. Weitzel J. N., Gonzalez K. D., Noltner K. A., Buzin C. H., Gu D., Wen-Fong C. Y., Nguyen V. Q., Han J. H., Lowstuter K., Longmate J., Sommer S. S., Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology 2009 27 8 1250 1256 2-s2.0-62449249871 10.1200/JCO.2008.16.6959
40. Chompret A., Brugières L., Ronsin M., Gardes M., Dessarps-Freichey F., Abel A., Hua D., Ligot L., Dondon M. G., Bressac-De Paillerets B., Frébourg T., Lemerle J., Bonaïti-Pellié C., Feunteun J., P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer 2000 82 12 1932 1937 2-s2.0-0034071085 (Pubitemid 30326453)
41. Nichols K. E., Malkin D., Garber J. E., Fraumeni J. F., Li F. P., Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology Biomarkers and Prevention 2001 10 2 83 87 2-s2.0-0035117108 (Pubitemid 32172424)
42. Gage M., Wattendorf D., Henry L. R., Translational advances regarding hereditary breast cancer syndromes. Journal of Surgical Oncology 2012 105 5 444 451
43. Lammens C. R. M., Bleiker E. M. A., Aaronson N. K., Wagner A., Sijmons R. H., Ausems M. G. E. M., Vriends A. H. J. T., Ruijs M. W. G., Van Os T. A. M., Spruijt L., Gómez García E. B., Cats A., Nagtegaal T., Verhoef S., Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits. Familial Cancer 2010 9 4 647 654 2-s2.0-78650217249 10.1007/s10689-010-9368-z
44. Lalloo F., Varley J., Ellis D., Moran A., O'Dair L., Pharoah P., Evans D. G. R., Redmond E., Shenton A., Bulman B., Bulman M., Howell A., Thorncroft M., McGown G., Seal S., Stratton M., Hodgson S., Mathew C., Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. The Lancet 2003 361 9363 1101 1102 2-s2.0-0037471838 10.1016/S0140-6736(03)12856-5 (Pubitemid 36369565)
45. Walsh T., Casadei S., Coats K. H., Swisher E., Stray S. M., Higgins J., Roach K. C., Mandell J., Lee M. K., Ciernikova S., Foretova L., Soucek P., King M. C., Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Journal of the American Medical Association 2006 295 12 1379 1388 2-s2.0-33645084562 10.1001/jama.295.12.1379
46. Olivier M., Goldgar D. E., Sodha N., Ohgaki H., Kleihues P., Hainaut P., Eeles R. A., Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Research 2003 63 20 6643 6650 2-s2.0-0142157701 (Pubitemid 37322942)
47. Birch J. M., Heighway J., Teare M. D., Kelsey A. M., Hartley A. L., Tricker K. J., Crowther D., Lane D. P., Santibanez-Koref M. F., Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. British Journal of Cancer 1994 70 6 1176 1181 2-s2.0-0028172939 (Pubitemid 24358958)
48. Garber J. E., Offit K., Hereditary cancer predisposition syndromes. Journal of Clinical Oncology 2005 23 2 276 292 2-s2.0-13744263782 10.1200/JCO.2005.10.042 (Pubitemid 46206879)
49. Eng C., Will the real Cowden syndrome please stand up: revised diagnostic criteria. Journal of Medical Genetics 2000 37 11 828 830 2-s2.0-0033738748
50. Starin T. M., van der Veen J. P. W., Arwert F., The Cowden syndrome: a clinical and genetic study in 21 patients. Clinical Genetics 1986 29 3 222 233 2-s2.0-0022649866 (Pubitemid 16136974)
51. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R., PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997 275 5308 1943 1947 2-s2.0-0030936323 10.1126/science.275.5308.1943 (Pubitemid 27148818)
52. Eng C., Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Annals of the New York Academy of Sciences 2002 968 213 221 2-s2.0-0036299115 (Pubitemid 34721882)
53. Allain D. C., Genetic counseling and testing for common hereditary breast cancer syndromes a Paper from the 2007 William Beaumont hospital symposium on molecular pathology. Journal of Molecular Diagnostics 2008 10 5 383 395 2-s2.0-52249093054 10.2353/jmoldx.2008.070161
54. Tomlinson I. P. M., Houlston R. S., Peutz-Jeghers syndrome. Journal of Medical Genetics 1997 34 12 1007 1011 2-s2.0-0030773520 (Pubitemid 27522107)
55. van Lier M. G. F., Wagner A., Mathus-Vliegen E. M. H., Kuipers E. J., Steyerberg E. W., Van Leerdam M. E., High cancer risk in peutz-jeghers syndrome: a systematic review and surveillance recommendations. American Journal of Gastroenterology 2010 105 6 1258 1265 2-s2.0-77953230425
56. Beggs A. D., Latchford A. R., Vasen H. F. A., Moslein G., Alonso A., Aretz S., Bertario L., Blanco I., Bülow S., Burn J., Capella G., Colas C., Friedl W., Møller P., Hes F. J., Järvinen H., Mecklin J. P., Nagengast F. M., Parc Y., Phillips R. K. S., Hyer W., Ponz De Leon M., Renkonen-Sinisalo L., Sampson J. R., Stormorken A., Tejpar S., Thomas H. J. W., Wijnen J. T., Clark S. K., Hodgson S. V., Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010 59 7 975 986 2-s2.0-77953985258 10.1136/gut.2009.198499
57. Gruber S. B., Entius M. M., Petersen G. M., Laken S. J., Longo P. A., Boyer R., Levin A. M., Mujumdar U. J., Trent J. M., Kinzler K. W., Vogelstein B., Hamilton S. R., Polymeropoulos M. H., Offerhaus G. J., Giardiello F. M., Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Research 1998 58 23 5267 5270 2-s2.0-0032403068 (Pubitemid 28551096)
58. Lim W., Olschwang S., Keller J. J., Westerman A. M., Menko F. H., Boardman L. A., Scott R. J., Trimbath J., Giardiello F. M., Gruber S. B., Gille J. J. P., Offerhaus G. J. A., De Rooij F. W. M., Wilson J. H. P., Spigelman A. D., Phillips R. K. S., Houlston R. S., Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004 126 7 1788 1794 2-s2.0-2942527434 10.1053/j.gastro.2004.03.014 (Pubitemid 38736344)
59. Giardiello F. M., Welsh S. B., Hamilton S. R., Increased risk of cancer in the Peutz-Jeghers syndrome. The New England Journal of Medicine 1987 316 24 1511 1514 2-s2.0-0023192463 (Pubitemid 17076235)
60. Spigelman A. D., Murday V., Phillips R. K. S., Cancer and the Peutz-Jeghers syndrome. Gut 1989 30 11 1588 1590 2-s2.0-0024350881 (Pubitemid 20001163)
61. Giardiello F. M., Brensinger J. D., Tersmette A. C., Goodman S. N., Petersen G. M., Booker S. V., Cruz-Correa M., Offerhaus J. A., Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000 119 6 1447 1453 2-s2.0-0034464147 (Pubitemid 32198669)
62. Hearle N., Schumacher V., Menko F. H., Olschwang S., Boardman L. A., Gille J. J. P., Keller J. J., Westerman A. M., Scott R. J., Lim W., Trimbath J. D., Giardiello F. M., Gruber S. B., Offerhaus G. J. A., De Rooij F. W. M., Wilson J. H. P., Hansmann A., Möslein G., Royer-Pokora B., Vogel T., Phillips R. K. S., Spigelman A. D., Houlston R. S., Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clinical Cancer Research 2006 12 10 3209 3215 2-s2.0-33744782567 10.1158/1078-0432.CCR-06-0083 (Pubitemid 43837371)
63. Graziano F., Humar B., Guilford P., The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Annals of Oncology 2003 14 12 1705 1713 2-s2.0-0348229127 10.1093/annonc/mdg486 (Pubitemid 38029040)
64. Pharoah P. D. P., Guilford P., Caldas C., Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001 121 6 1348 1353 2-s2.0-0035211026 (Pubitemid 33140452)
65. Keller G., Vogelsang H., Becker I., Hutter J., Ott K., Candidus S., Grundei T., Becker K. F., Mueller J., Siewert J. R., Höfler H., Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. American Journal of Pathology 1999 155 2 337 342 2-s2.0-0032806475 (Pubitemid 29370383)
66. Kangelaris K. N., Gruber S. B., Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer. Journal of the American Medical Association 2007 297 21 2360 2372 2-s2.0-34249979864
67. Kluijt I., Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer 2012 11 3 363 369
68. Brooks-Wilson A. R., Kaurah P., Suriano G., Leach S., Senz J., Grehan N., Butterfield Y. S. N., Jeyes J., Schinas J., Bacani J., Kelsey M., Ferreira P., MacGillivray B., MacLeod P., Micek M., Ford J., Foulkes W., Australie K., Greenberg C., LaPointe M., Gilpin C., Nikkel S., Gilchrist D., Hughes R., Jackson C. E., Monaghan K. G., Oliveira M. J., Seruca R., Gallinger S., Caldas C., Huntsman D., Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. Journal of Medical Genetics 2004 41 7 508 517 2-s2.0-3142695439 (Pubitemid 38932110)
69. Suriano G., Oliveira M. J., Huntsman D., Mateus A. R., Ferreira P., Casares F., Oliveira C., Carneiro F., Machado J. C., Mareel M., Seruca R., E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. Human Molecular Genetics 2003 12 22 3007 3016 2-s2.0-10744230392 10.1093/hmg/ddg316 (Pubitemid 37442028)
70. Stracker T. H., Usui T., Petrini J. H. J., Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair 2009 8 9 1047 1054 2-s2.0-68249126215 10.1016/j.dnarep.2009.04.012
71. Weischer M., Bojesen S. E., Ellervik C., Tybjærg-Hansen A., Nordestgaard B. G., CHEK2 -1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. Journal of Clinical Oncology 2008 26 4 542 548 2-s2.0-39149141409 10.1200/JCO.2007.12. 5922 (Pubitemid 351264346)
72. Easton D., CHEK2 -1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. The American Journal of Human Genetics 2004 74 6 1175 1182 2-s2.0-3042582651 10.1086/421251 (Pubitemid 38669316)
73. Narod S., Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clinical Genetics 2012 83 3 232 237 10.1111/j.1399-0004.2012.01906.x
74. Cybulski C., Gorski B., Huzarski T., Byrski T., Gronwald J., Debniak T., Wokotorczyk D., Jakubowska A., Serrano-Fernandez P., Dork T., Narod S. A., Lubinski J., Effect of CHEK2 missense variant 1157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. Journal of Medical Genetics 2009 46 2 132 135 2-s2.0-62149101575 10.1136/jmg.2008.061697
75. Mellemkjær L., Dahl C., Olsen J. H., Bertelsen L., Guldberg P., Christensen J., Børresen-Dale A. L., Stovall M., Langholz B., Bernstein L., Lynch C. F., Malone K. E., Haile R. W., Andersson M., Thomas D. C., Concannon P., Capanu M., Boice J. D., Bernstein J. L., Olsen J. H., Bernstein J. L., Børresen-Dale A. L., Borg Å.., Bertelsen L., Mellemkjær L., Guldberg P., Liang X., Wolitzer A., Seminara D., Haile R. W., Diep A. T., Zhou N., Liu Y., Ter-Karapetova E., Hernandez A., Orlow I., Bernstein L., Donnelly-Allen L., Lynch C. F., DeWall J., Malone K. E., Epstein N., Anton-Culver H., Largent J., Stovall M., Smith S., Shore R. E., Boice J. D., Langholz B. M., Thomas D. C., Begg C., Capanu M., Thompson W. D., Risk for contralateral breast cancer among carriers of the CHEK2 -1100delC mutation in the WECARE Study. British Journal of Cancer 2008 98 4 728 733 2-s2.0-39449090355 10.1038/sj.bjc.6604228 (Pubitemid 351272614)
76. Adank M. A., Jonker M. A., Kluijt I, CHEK2 -1100delC homozygosity is associated with a high breast cancer risk in women. Journal of Medical Genetics 2011 48 12 860 863
77. Cybulski C., Wokołorczyk D., Huzarski T., Byrski T., Gronwald J., Górski B., Dbniak T., Masojć B., Jakubowska A., van de Wetering T., Narod S. A., Lubiński J., A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Research and Treatment 2007 102 1 119 122 2-s2.0-33847163983 10.1007/s10549-006-9320-y (Pubitemid 46294966)
78. Cybulski C., Górski B., Huzarski T., Masojć B., Mierzejewski M., Dbniak T., Teodorczyk U., Byrski T., Gronwald J., Matyjasik J., Złowocka E., Lenner M., Grabowska E., Nej K., Castaneda J., Mdrek K., Szymańska A., Szymańska J., Kurzawski G., Suchy J., Oszurek O., Witek A., Narod S. A., Lubiński J., CHEK2 is a multiorgan cancer susceptibility gene. The American Journal of Human Genetics 2004 75 6 1131 1135 2-s2.0-8844220451 10.1086/426403 (Pubitemid 39532081)
79. Roeb W., Higgins J., King M. C., Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Human Molecular Genetics 2012 21 12 2738 2744
80. Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T., Jayatilake H., McGuffog L., Hanks S., Evans D. G., Eccles D., Easton D. F., Stratton M. R., PALB2, which encodes a BRCA2 -interacting protein, is a breast cancer susceptibility gene. Nature Genetics 2007 39 2 165 167 2-s2.0-33846625493 10.1038/ng1959 (Pubitemid 46184346)
81. Casadei S., Norquist B. M., Walsh T., Stray S., Mandell J. B., Lee M. K., Stamatoyannopoulos J. A., King M. C., Contribution of inherited mutations in the BRCA2 -interacting protein PALB2 to familial breast cancer. Cancer Research 2011 71 6 2222 2229 2-s2.0-79952741549 10.1158/0008-5472.CAN-10-3958
82. Jones S., Hruban R. H., Kamiyama M., Borges M., Zhang X., Parsons D. W., Lin J. C. H., Palmisano E., Brune K., Jaffee E. M., Iacobuzio-Donahue C. A., Maitra A., Parmigiani G., Kern S. E., Velculescu V. E., Kinzler K. W., Vogelstein B., Eshleman J. R., Goggins M., Klein A. P., Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009 324 5924 217 2-s2.0-64849092309 10.1126/science.1171202
83. Slater E. P., Langer P., Niemczyk E., Strauch K., Butler J., Habbe N., Neoptolemos J. P., Greenhalf W., Bartsch D. K., PALB2 mutations in European familial pancreatic cancer families. Clinical Genetics 2010 78 5 490 494 2-s2.0-77957333720 10.1111/j.1399-0004.2010.01425.x
84. Tischkowitz M., Capanu M., Sabbaghian N., Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Human Mutation 2012 33 4 674 680
85. Dansonka-Mieszkowska A., Kluska A., Moes J., Dabrowska M., Nowakowska D., Niwinska A., Derlatka P., Cendrowski K., Kupryjanczyk J., A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Medical Genetics 2010 11 1, article 20 2-s2.0-77649148280 10.1186/1471-2350-11-20
86. Brand R. E., Lerch M. M., Rubinstein W. S., Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007 56 10 1460 1469 (Pubitemid 47517845)
87. Langer P., Kann P. H., Fendrich V., Habbe N., Schneider M., Sina M., Slater E. P., Heverhagen J. T., Gress T. M., Rothmund M., Bartsch D. K., Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009 58 10 1410 1418 2-s2.0-70349318044 10.1136/gut.2008.171611
88. Canto M. I., Goggins M., Hruban R. H., Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clinical Gastroenterology and Hepatology 2006 4 6 766 781 (Pubitemid 43825802)
89. Abraham R. T., PI 3-kinase related kinases: "big" players in stress-induced signaling pathways. DNA Repair 2004 3 8-9 883 887 2-s2.0-3242882820 10.1016/j.dnarep.2004.04.002 (Pubitemid 38997930)
90. Ahmed M., Rahman N., ATM and breast cancer susceptibility. Oncogene 2006 25 43 5906 5911 2-s2.0-33749023605 10.1038/sj.onc.1209873 (Pubitemid 44453446)
91. Thompson D., Duedal S., Kirner J., McGuffog L., Last J., Reiman A., Byrd P., Taylor M., Easton D. F., Cancer risks and mortality in heterozygous ATM mutation carriers. Journal of the National Cancer Institute 2005 97 11 813 822 2-s2.0-20544474516 10.1093/jnci/dji141 (Pubitemid 40909124)
92. Gudmundsdottir K., Ashworth A., The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006 25 43 5864 5874 2-s2.0-33749023326 10.1038/sj.onc.1209874 (Pubitemid 44453442)
93. Chun H. H., Gatti R. A., Ataxia-telangiectasia, an evolving phenotype. DNA Repair 2004 3 8-9 1187 1196 2-s2.0-3242876404 10.1016/j.dnarep.2004.04.010 (Pubitemid 38997962)
94. Morrell D., Cromartie E., Swift M., Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. Journal of the National Cancer Institute 1986 77 1 89 92 2-s2.0-0022472723 (Pubitemid 16077187)
95. Seal S., Thompson D., Renwick A., Elliott A., Kelly P., Barfoot R., Chagtai T., Jayatilake H., Ahmed M., Spanova K., North B., McGuffog L., Evans D. G., Eccles D., Easton D. F., Stratton M. R., Rahman N., Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics 2006 38 11 1239 1241 2-s2.0-33750465216 10.1038/ng1902 (Pubitemid 44646283)
96. Rafnar T., Gudbjartsson D. F., Sulem P., Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics 2011 43 11 1104 1107
97. Catucci I., Milgrom R., Kushnir A., Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Familial Cancer 2012 11 3 483 491
98. Vaz F., Hanenberg H., Schuster B., Barker K., Wiek C., Erven V., Neveling K., Endt D., Kesterton I., Autore F., Fraternali F., Freund M., Hartmann L., Grimwade D., Roberts R. G., Schaal H., Mohammed S., Rahman N., Schindler D., Mathew C. G., Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nature Genetics 2010 42 5 406 409 2-s2.0-77951747926 10.1038/ng.570
99. Pennington K. P., Swisher E. M., Hereditary ovarian cancer: beyond the usual suspects. Gynecologic Oncology 2012 124 2 347 353
100. Pelttari L. M., Heikkinen T., Thompson D., Kallioniemi A., Schleutker J., Holli K., Blomqvist C., Aittomäki K., Bützow R., Nevanlinna H., RAD51C is a susceptibility gene for ovarian cancer. Human Molecular Genetics 2011 20 16 3278 3288 2-s2.0-79960815893 10.1093/hmg/ddr229
101. Osorio A., Endt D., Fernndez F., Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Human Molecular Genetics 2012 21 13 2889 2898
102. Hilbers F. S., Wijnen J. T., Hoogerbrugge N., Rare variants in XRCC2 as breast cancer susceptibility alleles. Journal of Medical Genetics 2012 49 10 618 620
103. Tambini C. E., Spink K. G., Ross C. J., Hill M. A., Thacker J., The importance of XRCC2 in RAD51-related DNA damage repair. DNA Repair 2010 9 5 517 525 2-s2.0-77952106719 10.1016/j.dnarep.2010.01.016
104. Park D. J., Lesueur F., Nguyen-Dumont T., Rare mutations in XRCC2 increase the risk of breast cancer. The American Journal of Human Genetics 2012 90 4 734 739
105. Lin W. Y., Camp N. J., Cannon-Albright L. A., A role for XRCC2 gene polymorphisms in breast cancer risk and survival. Journal of Medical Genetics 2011 48 7 477 484
106. Heikkinen K., Rapakko K., Karppinen S. M., Erkko H., Knuutila S., Lundán T., Mannermaa A., Børresen-Dale A. L., Borg Å., Barkardottir R. B., Petrini J., Winqvist R., RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006 27 8 1593 1599 2-s2.0-33747884830 10.1093/carcin/bgi360 (Pubitemid 44288048)
107. Heikkinen K., Karppinen S. M., Soini Y., Mäkinen M., Winqvist R., Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. Journal of Medical Genetics 2003 40 12, article e131 2-s2.0-1542542679
108. Desjardins S., Beauparlant J. C., Labrie Y., Ouellette G., Durocher F., Bessette P., Chiquette J., Laframboise R., Lépine J., Lespérance B., Pichette R., Plante M., Simard J., Variations in the NBN/NBS1 gene and the risk of breast cancer in non- BRCA1/2 French Canadian families with high risk of breast cancer. BMC Cancer 2009 9, article 181 2-s2.0-67650090387 10.1186/1471-2407-9-181
109. Bartkova J., Tommiska J., Oplustilova L., Aaltonen K., Tamminen A., Heikkinen T., Mistrik M., Aittomäki K., Blomqvist C., Heikkilä P., Lukas J., Nevanlinna H., Bartek J., Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Molecular Oncology 2008 2 4 296 316 2-s2.0-56649086648 10.1016/j.molonc.2008.09.007
110. Bogdanova N., Feshchenko S., Schürmann P., Waltes R., Wieland B., Hillemanns P., Rogov Y. I., Dammann O., Bremer M., Karstens J. H., Sohn C., Varon R., Dörk T., Nijmegen Breakage Syndrome mutations and risk of breast cancer. International Journal of Cancer 2008 122 4 802 806 2-s2.0-38349052915 10.1002/ijc.23168
111. Nseir S., Di Pompeo C., Soubrier S., Lenci H., Delour P., Onimus T., Saulnier F., Mathieu D., Durocher A., Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case-control study. Critical Care 2005 9 3 R238 245 2-s2.0-20444426336
112. Seemanova E., An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mutation Research 1990 238 3 321 324 2-s2.0-0025268280
113. Seemanová E., Jarolim P., Seeman P., Varon R., Digweed M., Swift M., Sperling K., Cancer risk of heterozygotes with the NBN founder mutation. Journal of the National Cancer Institute 2007 99 24 1875 1880 2-s2.0-38449120192 10.1093/jnci/djm251 (Pubitemid 351767197)
114. Ghimenti C., Sensi E., Presciuttini S., Brunetti I. M., Conte P., Bevilacqua G., Caligo M. A., Germline mutations of the BRCA1 -associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes and Cancer 2002 33 3 235 242 2-s2.0-0036165866 10.1002/gcc.1223 (Pubitemid 34130929)
115. Ratajska M., Antoszewska E., Piskorz A., Brozek I., Borg Å., Kusmierek H., Biernat W., Limon J., Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Research and Treatment 2012 131 1 89 97 2-s2.0-79951853503 10.1007/s10549-011-1403-8
116. Wang B., Matsuoka S., Ballif B. A., Zhang D., Smogorzewska A., Gygi S. P., Elledge S. J., Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007 316 5828 1194 1198 2-s2.0-34249946686 10.1126/science.1139476 (Pubitemid 46877482)
117. Solyom S., Aressy B., Pylkas K., Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Science Translational Medicine 2012 4 122 122ra23
118. Heyer W. D., Ehmsen K. T., Liu J., Regulation of homologous recombination in eukaryotes. Annual Review of Genetics 2010 44 113 139 2-s2.0-78149425175 10.1146/annurev-genet-051710-150955
119. Schild D., Lio Y. C., Collins D. W., Tsomondo T., Chen D. J., Evidence for simultaneous protein interactions between human Rad51 paralogs. The Journal of Biological Chemistry 2000 275 22 16443 16449 2-s2.0-0034596020 10.1074/jbc.M001473200 (Pubitemid 30398864)
120. Loveday C., Turnbull C., Ramsay E., Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics 2011 43 9 879 882
121. Osher D. J., de Leeneer K., Michils G., Mutation analysis of RAD51D in non- BRCA1/2 ovarian and breast cancer families. British Journal of Cancer 2012 106 8 1460 1463
122. Wickramanyake A., Bernier G., Pennil C., Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecologic Oncology 2012 127 3 552 555
123. Pelttari L. M., Kiiski J., Nurminen R., A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. Journal of Medical Genetics 2012 49 7 429 432
124. Easton D. F., Pooley K. A., Dunning A. M., Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007 447 7148 1087 1093 (Pubitemid 47014426)
125. Hunter D. J., Kraft P., Jacobs K. B., Cox D. G., Yeager M., Hankinson S. E., Wacholder S., Wang Z., Welch R., Hutchinson A., Wang J., Yu K., Chatterjee N., Orr N., Willett W. C., Colditz G. A., Ziegler R. G., Berg C. D., Buys S. S., McCarty C. A., Feigelson H. S., Calle E. E., Thun M. J., Hayes R. B., Tucker M., Gerhard D. S., Fraumeni J. F., Hoover R. N., Thomas G., Chanock S. J., A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics 2007 39 7 870 874 2-s2.0-34250001297 10.1038/ng2075 (Pubitemid 47014500)
126. Ahmed S., Thomas G., Ghoussaini M., Newly discovered breast cancer susceptibility loci on 3p24 and 17q23. Nature Genetics 2009 41 5 585 590
127. Thomas G., Jacobs K. B., Kraft P., Yeager M., Wacholder S., Cox D. G., Hankinson S. E., Hutchinson A., Wang Z., Yu K., Chatterjee N., Garcia-Closas M., Gonzalez-Bosquet J., Prokunina-Olsson L., Orr N., Willett W. C., Colditz G. A., Ziegler R. G., Berg C. D., Buys S. S., McCarty C. A., Feigelson H. S., Calle E. E., Thun M. J., Diver R., Prentice R., Jackson R., Kooperberg C., Chlebowski R., Lissowska J., Peplonska B., Brinton L. A., Sigurdson A., Doody M., Bhatti P., Alexander B. H., Buring J., Lee I. M., Vatten L. J., Hveem K., Kumle M., Hayes R. B., Tucker M., Gerhard D. S., Fraumeni J. F., Hoover R. N., Chanock S. J., Hunter D. J., A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics 2009 41 5 579 584 2-s2.0-67349158067 10.1038/ng.353
128. Zheng W., Long J., Gao Y. T., Li C., Zheng Y., Xiang Y. B., Wen W., Levy S., Deming S. L., Haines J. L., Gu K., Fair A. M., Cai Q., Lu W., Shu X. O., Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nature Genetics 2009 41 3 324 328 2-s2.0-61349163553 10.1038/ng.318
129. Cox A., Dunning A. M., Garcia-Closas M., A common coding variant in CASP8 is associated with breast cancer risk. Nature Genetics 2007 39 3 352 358 (Pubitemid 46328496)
130. Milne R. L., Gaudet M. M., Spurdle A. B., Fasching P. A., Couch F. J., Benítez J., Arias Pérez J. I., Zamora M. P., Malats N., dos Santos Silva I., Gibson L. J., Fletcher O., Johnson N., Anton-Culver H., Ziogas A., Figueroa J., Brinton L., Sherman M. E., Lissowska J., Hopper J. L., Dite G. S., Apicella C., Southey M. C., Sigurdson A. J., Linet M. S., Schonfeld S. J., Freedman D. M., Mannermaa A., Kosma V. M., Kataja V., Auvinen P., Andrulis I. L., Glendon G., Knight J. A., Weerasooriya N., Cox A., Reed M. W. R., Cross S. S., Dunning A. M., Ahmed S., Shah M., Brauch H., Ko Y. D., Brüning T., Brauch H., Lambrechts D., Reumers J., Smeets A., Wang-Gohrke S., Hall P., Czene K., Liu J., Irwanto A. K., Chenevix-Trench G., Holland H., Fab K. C., Giles G. G., Baglietto L., Severi G., Bojensen S. E., Nordestgaard B. G., Flyger H., John E. M., West D. W., Whittemore A. S., Vachon C., Olson J. E., Fredericksen Z., Kosel M., Hein R., Vrieling A., Flesch-Janys D., Heinz J., Beckmann M. W., Heusinger K., Ekici A. B., Haeberle L., Humphreys M. K., Morrison J., Easton D. F., Pharoah P. D., García-Closas M., Goode E. L., Chang-Claude J., Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research 2010 12 6, article R110 2-s2.0-78650650205 10.1186/bcr2797